3 assets in Poorly Differentiated Chordoma

Therapeutic assets addressing Poorly Differentiated Chordoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Poorly Differentiated Chordoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Fludeoxyglucose Poorly Differentiated Chordoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Tiragolumab Poorly Differentiated Chordoma	National Cancer Institute (NCI)	P1/2	CCC (48)